POTTERS BAR, England and
HYDERABAD, India, April 23, 2015 /PRNewswire/ -- Mylan N.V.
(Nasdaq: MYL) today announced that its subsidiary, Mylan
Pharmaceuticals Private Limited, has launched generic Sofosbuvir
400 mg tablets under the brand name MyHep™ in
India. The product is indicated
for the treatment of chronic hepatitis C, a blood-borne infectious
disease that affects more than 100 million people in the developing
world, including approximately 12 million people in India.1,2
In September 2014, Mylan entered
into a licensing and technology transfer agreement with Gilead
granting Mylan the non-exclusive rights to manufacture and
distribute generic Sofosbuvir in 91 developing countries, including
India.
Mylan President Rajiv Malik said,
"The launch of Mylan's MyHep offers hope to millions of hepatitis C
patients in India who are in need
of a high quality, effective and affordable treatment option. We
look forward to bringing that same hope to millions of more
hepatitis C patients as we expand access to MyHep in the
developing world."
MyHep is an important addition to Mylan's growing commercial
business in India and is sold by
Mylan's dedicated sales force as part of its Hepato Care segment.
The company also offers four additional unique and innovative
segments – Critical Care, HIV Care, Women's Care and Oncology.
This press release includes statements that constitute
"forward-looking statements," including with regard to sales of
products, product approvals and the company's strategy, future
growth and performance. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: the impacts of competition; changes in
economic and financial conditions of the company's business;
strategies by competitors or other third parties to delay or
prevent product introductions; risks inherent in legal and
regulatory processes; risks associated with international
operations; uncertainties and matters beyond the control of
management; and the other risks detailed in the company's filings
with the Securities and Exchange Commission. The company undertakes
no obligation to update these statements for revisions or changes
after the date of this release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of around 1,400 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral
therapies, upon which approximately 40% of HIV/AIDS patients in
developing countries depend. We also operate one of the largest
active pharmaceutical ingredient manufacturers and currently market
products in about 145 countries and territories. Our workforce of
approximately 30,000 people is dedicated to creating better health
for a better world, one person at a time. Learn more at
mylan.com.
- World Health Organization. Hepatitis C Surveillance and
Control.
http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html.
Accessed on Jan. 15, 2015.
- World Health Organization. "Guidelines for the screening, care
and treatment of persons with hepatitis C infection." April 2014.
Photo - http://photos.prnewswire.com/prnh/20150423/201075
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-sofosbuvir-tablets-myhep-in-india-300070861.html
SOURCE Mylan N.V.